Table 1 Clinical characteristics associated with stroke recurrence (SR) after 90 days follow-up.
From: Lipidomic signature of stroke recurrence after transient ischemic attack
All N = 460 | Non-SR N = 423 (92.0%) | SR N = 37 (8.0%) | p valuea | |
|---|---|---|---|---|
Age, mean (SD) | 71.4 (13.6) | 71.4 (13.6) | 70.4 (14.3) | 0.662 |
Female, n (%) | 221 (48.0) | 198 (46.8) | 23 (62.2) | 0.086 |
Previous ischemic stroke, n (%) | 32 (7.0) | 25 (5.9) | 7 (18.9) | 0.003 |
Hypertension, n (%) | 327 (71.1) | 303 (71.6) | 24 (64.9) | 0.384 |
IHD, n (%) | 56 (12.2) | 53 (12.5) | 3 (8.1) | 0.43 |
Atrial fibrillation | 112 (24.3) | 101 (23.9) | 11 (29.7) | 0.426 |
Diabetes mellitus, n (%) | 122 (26.5) | 111 (26.2) | 11 (29.7) | 0.645 |
Smoking, n (%) | 25 (5.4) | 24 (5.7) | 1 (2.7) | 0.445 |
Hypercholesterolemia, n (%) | 224 (48.7) | 208 (49.2) | 16 (43.29 | 0.489 |
Cluster TIA, n (%) | 90 (19.6) | 80 (18.9) | 10 (27.0) | 0.233 |
Duration | 0.09 | |||
< 10’ | 86 (18.7) | 84 (19.9) | 2 (5.4) | |
10’–60’ | 203 (44.1) | 185 (43.7) | 18 (48.6) | |
> 60’, n (%) | 171 (37.2) | 154 (36.4) | 17 (45.9) | |
Motor impairment, n (%) | 245 (53.3) | 218 (51.5) | 27 (73.0) | 0.012 |
ABCD2 groups | ||||
0–3 | 116 (25.2) | 110 (26.09 | 6 (16.2) | 0.106 |
4–5 | 252 (54.8) | 233 (55.1) | 19 (51.4) | |
6–7 | 92 (20.09 | 80 (18.9) | 12 (32.4) | |
DWI abnormality, n (%) | 80 (36.7) | 64 (32.7) | 16 (72.7) | < 0.001 |
Etiology, n(%) | ||||
LAA | 94 (20.4) | 81 (19.1) | 13 (35.1) | 0.021 |
CE | 125 (27.2) | 113 (29.1) | 12 (32.4) | 0.453 |
SV | 130 (28.3) | 123 (29.1) | 7 (18.9) | 0.188 |
Undetermined | 104 (22.6) | 100 (23.6) | 4 (10.8) | 0.099 |
Cholesterol total, mean (SD) mg/dL | 180.2 (45.6) | 180.8 (46.3) | 174.5 (38.1) | 0.509 |
LDL, mean (SD) mg/dL | 111.1 (36.7) | 111.4 (37.6) | 107.2 (25.5) | 0.639 |
HDL, mean (SD) mg/dL | 47.4 (13.4) | 47.2 (12.8) | 48.9 (18.5) | 0.578 |
Triglycerides, mean (SD) mg/dL | 134.2 (86.8) | 135.6 (89.0) | 120.3 (61.4) | 0.413 |
Previous statin treatment, n (%) | 146 (33.7) | 135 (34.0) | 11 (30.6) | 0.675 |
